Omar EL KHATIB, Maguy CHIHA, Rabih HIJAZI, Ola JARAD, Cynthia SALLOUM, Khaled EL BABA, Ruba DAJANI, Salma AL SHAQFA, Sandra EL HAJJ
Experimental and Clinical Transplantation - 2026;24(2):173-181
Objectives: Diabetes mellitus, including new-onset diabetes after transplant, is a prevalent complication in solid-organ transplant recipients, often necessitating complex glycemic management. Glucagon-like peptide-1 receptor agonists, including semaglutide and tirzepatide, have shown promising outcomes in the general population, but comparative data in solid-organ transplant recipients are limited. In this study, we evaluated and compared the efficacy and safety of semaglutide and tirzepatide in a diverse cohort of solid-organ transplant recipients.
